Business Context and Reporting Period
This Form 8-K is filed by CalciMedica, Inc. on December 20, 2024. The report addresses the resumption of an at-the-market (ATM) equity offering program previously suspended on October 30, 2024.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the authorization of a new equity offering capacity.
- Offering Capacity: Up to $4,450,000 in aggregate gross sales price.
- Instrument: Common Stock, $0.0001 par value per share.
- Trading Symbol: CALC (Nasdaq Capital Market).
Material Changes
The primary material change is the reinstatement of the Company's ability to sell shares under its existing Offering Agreement with H.C. Wainwright & Co. The Company had suspended sales under the prospectus dated August 11, 2023 (supplemented March 29, 2024) since October 30, 2024. On December 20, 2024, the Company filed a Current Prospectus Supplement to resume these sales.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the standard legal opinion regarding the legality of the shares. The document notes that the Company is an emerging growth company.
Investor Verification Checklist
- Verify the current market price of CALC to assess the potential dilution impact of the $4,450,000 offering capacity.
- Review the full text of the Current Prospectus Supplement filed on December 20, 2024, for updated use of proceeds.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.
- Check for any subsequent filings indicating if shares have actually been sold under the reinstated agreement.